Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia. According to GlobalData, Pre-Registration drugs for Postherpetic Neuralgia have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Lidocaine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lidocaine overview
lidocaine (MRX-5LBT) is under development for the treatment nerve pain associated with shingles (post-herpetic neuralgia, a severe neuropathic pain condition). The therapeutic candidate is administered transdermally which is formulated as patch. The development of the drug candidate is based on the ionic liquid transdermal system (ILTS) technology.
MEDRx overview
MEDRx through its subsidiaries carries out development of pharmaceutical drug based on the transdermal absorption system. The company’s pipeline products include CPN-101 (MRX-4TZT) treats pasticity; MRX-5LBT is for the treatment of neuropathic pain; MRX-9FLT and MRX-10XT for moderate to severe pain; MRX-7MLL targets alzheimer’s disease; MRX-6LDT for Chronic Pain; ALT-101 treats schizophrenia. It partners with many pharmaceutical companies for development of various drugs. The company operates across the US and Japan. MEDRx is headquartered in Higashikagawa City, Japan.
For a complete picture of Lidocaine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
